Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Documents

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

H.C. Wainwright & Co.
Jason Kolbert

Maxim Group
Jason McCarthy

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018

As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types.

IsoRay Names Jonathan Hunt New Chief Financial Officer

RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy...

ASTRO 2018 Insights: building community, innovating and celebrating strong data around the power of Cesium

Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of...

Study Shows Significantly Improved Survival Rate of Cervical Cancer Patients after Receiving Brachytherapy and EBRT

The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.

IsoRay Announces First Quarter Fiscal 2019 Financial Results

Year Over Year First Quarter Revenues Increased 29% Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter   RICHLAND,...

Breakthroughs in brachytherapy by Cesium Pioneers.

Doctors across the US are using Cesium-131 by Isoray in powerful ways with great outcomes. Check out their work.

The ability to deliver high concentrated radiation treatment in a tightly controlled area at the time of surgery really allows us to customize and individualize cancer treatment for our patients.

Dr. Adam J. Luginbuhl, MD

Otolaryngology/Head & Neck Surgery - Head & Neck Cancers, Thomas Jefferson University Hospital